drugset / Trial / NCT01095809
Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether intravitreous bevacizumab or intravitreous triamcinolone acetonide are effective and safe in the treatment of uveitic macular oedema
Timeline
- Start
- 2010-04
- Primary completion
- 2013-04
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 2.5 mg | Other |
| Subject | Triamcinolone Acetonide | Other / unclassified | 2 mg | Other |